Showing results (1911-1920 of 2,001) with videos related to
Sort By:
Pageof 201
Journal of Medicinal Chemistry|November 28, 2006
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillationB Wesley Trotter, Kausik K Nanda, Nathan R Kett, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor AntagonistIan M Bell, Steven N Gallicchio, Michael R Wood, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.Bioorganic & Medicinal Chemistry Letters|February 8, 2011
P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 positionRichard C A Isaacs, Christina L Newton, Kellie J Cutrona, et al.Bioorganic & Medicinal Chemistry Letters|February 8, 2011
Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitorsRichard C A Isaacs, Christina L Newton, Kellie J Cutrona, et al.Molecular Pharmacology|November 23, 2005
Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in ratsRichard M Brochu, Ivy E Dick, Jason W Tarpley, et al.The Journal of Pharmacology and Experimental Therapeutics|November 14, 1997
Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptorS Patel, S Freedman, K L Chapman, et al.Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trialsDaphne W Bell, Thomas J Lynch, Sara M Haserlat, et al.EMBO Molecular Medicine|May 1, 2010
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineDora Dias-Santagata, Sara Akhavanfard, Serena S David, et al.Pageof 201